Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

NCT01583218 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.

NCT NCT01583218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01583218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Lead sponsor
Portola Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
January 31, 2016
Enrollment
7,513 (actual)
Sites
462

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism (vte)